drugset / Trial / NCT07269769

A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD

NCT07269769

Phase 3 Not yet recruiting 450 enrolled Tasly Pharmaceutical Group Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the TSL-TCM-SHJSMW-Ⅲ study is to study the efficacy and safety of Sanhuang Jingshiming Pills in subjects with Neovascular Age-Related Macular Degeneration.

Timeline

Start
2026-04-30
Primary completion
2031-12-31
Completion
2031-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Sanhuang Jingshiming Unknown 1 unknown
Background Ranibizumab Monoclonal antibody

Indications

No indication recorded.